Halozyme Therapeutics, Inc.
HALOHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeHalozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and. Valued at $8.08B, HALO is a mid-cap name in its sector. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Market Cap
$8.08B
Beta
0.88
P/E (TTM)
23.91
P/E (Fwd)
6.89
EPS (TTM)
$2.85
EPS (Fwd)
$9.89
ROE
99.4%
ROA
22.1%
Cash
$318.6M
Total Debt
$2.18B
Free CF
$228.1M
52W Change
27.8%
Annual Financials
Cash vs Debt
Halozyme Therapeutics, Inc. carries $2.18B in total debt against $318.6M in cash reserves — debt is roughly 6.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $228.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 99.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 22.1% further supports the picture of efficient asset utilization. Revenue has grown from $660.1M (2022) to $1.40B (2025), reflecting a 112% increase over the period.
Halozyme Therapeutics, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Halozyme Therapeutics, Inc.'s trajectory.